ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
159.4 EUR
-0.1 (-0.06%)
Taking everything into account, ZEG scores 5 out of 10 in our fundamental rating. ZEG was compared to 55 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are concerns on its financial health. ZEG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
In the past year ZEG had a positive cash flow from operations.
ZEG had positive earnings in each of the past 5 years.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
ZEG's Return On Assets of 8.21% is fine compared to the rest of the industry. ZEG outperforms 67.27% of its industry peers.
The Return On Equity of ZEG (20.48%) is better than 67.27% of its industry peers.
ZEG's Return On Invested Capital of 14.42% is fine compared to the rest of the industry. ZEG outperforms 70.91% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 13.92%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
With a decent Profit Margin value of 16.17%, ZEG is doing good in the industry, outperforming 65.45% of the companies in the same industry.
ZEG's Profit Margin has improved in the last couple of years.
The Operating Margin of ZEG (24.34%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG's Gross Margin of 81.90% is amongst the best of the industry. ZEG outperforms 81.82% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ZEG has been increased compared to 5 years ago.
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.00 indicates that ZEG is not in any danger for bankruptcy at the moment.
ZEG has a better Altman-Z score (6.00) than 81.82% of its industry peers.
ZEG has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ZEG would need 3.41 years to pay back of all of its debts.
ZEG has a Debt to FCF ratio (3.41) which is comparable to the rest of the industry.
ZEG has a Debt/Equity ratio of 0.61. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio (0.61) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 6 |
ROIC/WACC1.6
WACC9.01%
2.3 Liquidity
A Current Ratio of 0.88 indicates that ZEG may have some problems paying its short term obligations.
ZEG has a Current ratio of 0.88. This is amonst the worse of the industry: ZEG underperforms 81.82% of its industry peers.
A Quick Ratio of 0.69 indicates that ZEG may have some problems paying its short term obligations.
ZEG has a worse Quick ratio (0.69) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
ZEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.
Based on estimates for the next years, ZEG will show a small growth in Revenue. The Revenue will grow by 7.17% on average per year.
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.45%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.17%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.20, the valuation of ZEG can be described as rather expensive.
ZEG's Price/Earnings is on the same level as the industry average.
ZEG is valuated rather cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 17.39, which indicates a rather expensive current valuation of ZEG.
ZEG's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (36.56), we can say ZEG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.2 | ||
| Fwd PE | 17.39 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 69.09% of the companies listed in the same industry.
ZEG's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 67.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.75 | ||
| EV/EBITDA | 28.7 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
A more expensive valuation may be justified as ZEG's earnings are expected to grow with 12.91% in the coming years.
PEG (NY)1.46
PEG (5Y)1.09
EPS Next 2Y13.64%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.75%, ZEG has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.86, ZEG has a dividend in line with its industry peers.
Compared to the average S&P500 Dividend Yield of 2.32, ZEG is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.75% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
52.89% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
FRA:ZEG (11/28/2025, 7:00:00 PM)
159.4
-0.1 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap494.23B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target160.15 (0.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.75% |
Yearly Dividend2.58
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)3.4%
PT rev (3m)2.51%
EPS NQ rev (1m)-0.17%
EPS NQ rev (3m)-1.88%
EPS NY rev (1m)0.05%
EPS NY rev (3m)0.09%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.2 | ||
| Fwd PE | 17.39 | ||
| P/S | 9.83 | ||
| P/FCF | 59.75 | ||
| P/OCF | 37.76 | ||
| P/B | 12.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.7 |
EPS(TTM)7.89
EY4.95%
EPS(NY)9.17
Fwd EY5.75%
FCF(TTM)2.67
FCFY1.67%
OCF(TTM)4.22
OCFY2.65%
SpS16.21
BVpS12.8
TBVpS-3.77
PEG (NY)1.46
PEG (5Y)1.09
Graham Number47.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 6 |
F-Score7
WACC9.01%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 20.2 and the Price/Book (PB) ratio is 12.46.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.